Detailed Explanation
A SUSAR represents a particularly significant safety finding in clinical trials, combining three critical elements: the event is serious according to regulatory definitions, there is a reasonable possibility that the investigational product caused the event, and the nature or severity of the event is not consistent with the applicable reference safety information. This convergence of seriousness, suspected causality, and unexpectedness triggers the most stringent regulatory reporting requirements in drug development.